GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Genomtec GMT.WA · PLN

N/A · GPW · 🇵🇱 Poland

Compare

2.42

-0.82%

Close of 9 Nov 2026, in PLN

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Genomtec

Its shares trade on GPW under the ticker GMT.WA. It has been listed since 17 March 2021. In the fiscal year to 31 December 2025, it reported revenue of PLN 21,000 and a net loss of PLN 10.4m. At that date it held total assets of PLN 15.4m and shareholders' equity of PLN 9.2m.

Genomtec SA engages in the research and development of molecular diagnostic equipment. The company is headquartered in Wroclaw, Woj. Dolnoslaskie. The company went IPO on 2021-03-17. The firm is focused on development of of Genomtec ID, a mobile platform for genetic diagnosis in the point of patient care. Its creation and commercialization allows the diagnostic process to be executed in point of care setting, such as: primary care clinics, pharmacies, doctor’s offices, hospital emergency departments (ERs) without the need for complicated and time-consuming laboratory workflow conducted by qualified personnel.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
17 Mar 2021

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Genomtec ID mobile platform enables genetic diagnosis in primary care clinics without lab workflows.
  • Point-of-care diagnostics reduce time and complexity for genetic testing in ERs and pharmacies.
  • Wroclaw headquarters supports R&D in molecular diagnostics for healthcare settings.

Weaknesses

  • Genomtec SA's IPO on 17 March 2021 may indicate limited market presence.
  • Focus on mobile diagnostics might restrict broader application in complex medical scenarios.
  • Wroclaw location could limit access to global biotech talent pools.

Opportunities

  • Expansion into European healthcare markets for point-of-care genetic testing solutions.
  • Growing demand for rapid diagnostics in primary care and pharmacy settings across Europe.
  • Partnerships with healthcare providers to integrate Genomtec ID into ER workflows.

Threats

  • Competition from established molecular diagnostic equipment providers in Europe.
  • Regulatory changes affecting point-of-care diagnostic device approvals in Poland.
  • Economic downturns reducing healthcare spending on new diagnostic technologies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.